Alzheimer’s Disease (AD) is the most common cause of dementia. With the incidence rate doubling every 5 years after the age of 65, AD poses significant medical, social and socioeconomic challenges. Due to the fact that the cortical atrophy associated with AD can be detected
in vivo using MRI, neuroimaging measures have been playing an increasingly important role in searching for bio-markers of AD that can be used for early diagnosis, progression monitoring and also therapy responses measure. Recent studies have focused on individuals with mild cognitive impairment (MCI), a concept used to describe a high-risk ‘pre-dementia’ state (the prodromal stage of Alzheimer’s disease (
Dubois et al., 2007)), in which a deterioration of cognitive skills can be measured while the ability to manage tasks of daily living remains intact (
Petersen et al., 1999;
Petersen, 2004). According to epidemiological studies, each year 6~25% of subjects with MCI eventually convert to clinical AD, which is a markedly higher annual rate of conversion than that observed in normal elderly control population, which is around 1% (
Petersen, 2001). However, MCI is a heterogeneous group. There have been approaches to more precisely define different MCI clinical presentations (
Petersen, 2004). When individuals have impairments in domains other than memory it is classified as non-amnestic single- or multiple-domain MCI and these individuals are believed to be more likely to convert to other dementias. Additionally, when memory loss is the predominant symptom, it is termed ‘amnestic’ MCI. Subjects in this subtype show greatest risk for conversion to AD in 6 years. These MCI subjects finally develop probable AD, which are referred to as Progressive-MCI (P-MCI). In contrast, some other MCI subjects do not convert to AD even after several years of follow-up, which are referred to as Stable-MCI (S-MCI). Therefore, more and more emphasis has been placed on identifying those P-MCI individuals from the MCI group. Successful identification of such individuals at an early-stage before the onset of clinical symptoms may lead to effective intervention of pharmacological treatments for AD as they become available.
It has been shown that many P-MCIs present evolving AD-like patterns of brain atrophy. Therefore, to find out how AD-induced GM atrophy spreads spatially and temporally in the brain, many longitudinal studies of normal aging or AD-degenerated cortical thinning have been conducted, in which GM volume/density are measured and analyzed within regions of interest (ROIs) or voxel-wisely (
Resnick et al., 2003;
Thompson et al., 2003;
Toga and Thompson, 2003;
Gogtay et al., 2004;
Thompson et al., 2004;
Chételat et al., 2005;
Davatzikos et al., 2009;
Desikan et al., 2009;
Dickerson et al., 2009). Recently, cortical thickness is also proposed as a more stable parameter for AD diagnosis than volume/density measures, because it is a more direct measure of GM atrophy due to the cytoarchitectural feature of the GM (
Regeur, 2000;
Singh et al., 2006). Hence, as an alternative to volumetric measures, the assessment of thickness of the cerebral cortex has been recently proposed as a more sophisticated way to measure brain atrophy resulting from the AD neuropathological changes (
Lerch et al., 2005). This measure has been proven both precise and sensitive in detecting alterations in cortical morphology (
Lerch and Evans, 2005). Cortical thickness analysis has been successfully used in various studies as markers to separate AD patients from healthy controls and MCI subjects (
Chételat et al., 2005;
Singh et al., 2006;
Du et al., 2007;
Desikan et al., 2009;
Hutton et al., 2009). In addition, more recently, attempts to distinguish P-MCI from S-MCI by analyzing the baseline cortical thickness have also been reported (
Querbes et al., 2009).
So far, although there are plenty of longitudinal thickness studies focused on the comparative analysis between different clinical groups (
Toga and Thompson, 2003;
Chételat et al., 2005;
Lerch et al., 2005;
Thompson et al., 2004;
Singh et al., 2006), research work on classification or AD conversion prediction using the longitudinal cortical thickness changes still remains scarce. Compared to the volumetric measure, the obstacles in incorporating longitudinal thickness change information into the classification largely come from the difficulties in measuring the subtle longitudinal thickness changes accurately and reliably. Comparing the thickness of cortical structures (1.2~4.5 mm) with the resolution of MR images (~1 mm), cortical structures are only a few voxels thick in the images and the possible errors in the measuring process could be considerably large. This situation becomes even worse when the thickness at different time-points are measured independently, because the expected change in GM thickness during the early stage of AD is less than 1
mm in most brain regions (
Lerch et al., 2005;
Singh et al., 2006), which can be easily overwhelmed by the noises. In our recently developed 4D cortical thickness measuring method (
Li et al., 2010), the accuracy and the robustness of thickness measurement for longitudinal images have been significantly improved by incorporating the information from all time-points as a constraint or guidance to each other. This leads to a much higher correlation detected between the thickness measured by our method and the MMSE (Mini-Mental State Examination score (
Folstein et al., 1975)) or CDR-SOB (Clinical Dementia Rating-Sum of Boxes (
Morris, 1993)) scores, when compared with the common 3D measuring method.
With this 4D cortical thickness measuring method, in this study, experiments are designed to compare the thickness change patterns among four different clinical groups (AD, NC, S-MCI and P-MCI). Besides comparing the static features (such as thickness measured at each time-point), the temporal dynamic measures are also extracted, such as the thinning speed (mm/year) and thinning ratio (endline/baseline). In addition, to capture the system-level information, a brain network is first constructed based on the correlation of longitudinal cortical thickness changes between different ROIs, and then the network clustering coefficient (
Rubinov and Sporns, 2009) which represents the wiring efficiency of the network is also extracted as feature in this study. Finally, we combine these three different categories of features to find 4D patterns that can be used to effectively diagnose AD or predict the MCI converters (the P-MCI patients) in MCI group.